## MRK: Merck & Company, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.7% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($93.83)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Merck & Co., (MRK) Gets Conditional Approval For EXZOLT CATTLE-CA1**
- Source: Finviz | 20251211T130838 | Bullish | Relevance: 99%
- Merck & Co., (MRK) has received conditional FDA approval for EXZOLT CATTLE-CA1, a topical solution for treating New World screwworm infestations, with availability expected in Q1 2025. This approval was accelerated by the FDA's priority zoonotic drug designation. Analysts at Guggenheim raised their price target for Merck & Co., Inc. due to anticipated revenues from Winrevair, which they believe could generate over $5 billion annually if Phase 3 trials succeed.

**2. EDENTREE ASSET MANAGEMENT Ltd Purchases 15,000 Shares of Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251211T094831 | Bullish | Relevance: 99%
-  EDENTREE ASSET MANAGEMENT Ltd increased its stake in Merck & Co., Inc. (NYSE:MRK) by 14.2%, acquiring an additional 15,000 shares to hold a total of 120,865 shares valued at $9.56 million. Merck recently surpassed EPS estimates, reported strong revenue, and raised its quarterly dividend to $0.85 per share. Institutional investors collectively own about 76.07% of Merck's stock, indicating significant interest.

**3. Merck & Co., (MRK) Gets Conditional Approval For EXZOLT CATTLE-CA1**
- Source: Yahoo Finance | 20251211T120842 | Bullish | Relevance: 99%
-  Merck & Co., Inc. (NYSE: MRK) recently received conditional FDA approval for EXZOLT CATTLE-CA1, a topical solution for preventing and treating New World screwworm larvae infestations in cattle. The FDA accelerated this approval due to the drug's priority zoonotic drug designation. Analysts at Guggenheim increased their price target for MRK to $122, citing the potential $5 billion annual revenue from Winrevair if Phase 3 trials are successful.

**4. Axa S.A. Sells 13,668 Shares of Merck & Co., Inc. $MRK**
- Source: MarketBeat | 20251209T080900 | Somewhat-Bullish | Relevance: 99%
-  Axa S.A. has reduced its stake in Merck & Co., Inc. by 1.0%, selling 13,668 shares to now own 1,306,332 shares valued at approximately $103.4 million. Other institutional investors have both increased and decreased their positions in Merck, while EVP David Michael Williams also sold 8,614 shares. Merck recently reported strong quarterly earnings, increased its dividend, and has received varied analyst ratings with a consensus "Hold."

**5. MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy?**
- Source: Finviz | 20251209T171326 | Neutral | Relevance: 98%
-  Merck's MRK stock has consistently traded above its 50-day and 200-day simple moving averages since early November, signaling sustained bullish momentum. The article delves into Merck's strengths, particularly its blockbuster drug Keytruda and robust pipeline, as well as challenges like Keytruda's upcoming patent expiration and declining Gardasil sales in China. Despite recent price recovery and discounted valuation, the author suggests a "wait-and-see" approach for investors due to these challenges.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Scotiabank | $120 | $105 | +14% |
| 2025-12-02 | Goldman Sachs | $120 | $92 | +30% |
| 2025-11-24 | Wells Fargo | $125 | $90 | +39% |
| 2025-11-18 | Deutsche Bank | $111 | $110 | +1% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Scotiabank | main | Sector Outperform |
| 2025-12-02 | Goldman Sachs | main | Buy |
| 2025-11-24 | Wells Fargo | up | Overweight |
| 2025-11-18 | Deutsche Bank | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.09M) |
| Sells | 2 ($1.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.2% (-0.3%)
- Blackrock Inc.: 8.7% (-1.6%)
- State Street Corpora: 4.8% (-0.3%)
- Wellington Managemen: 3.0% (-2.0%)
- JPMORGAN CHASE & CO: 2.8% (+121.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 4 raises (avg +21%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.80 indicates undervaluation relative to growth. Quality metrics strong (ROE 40%, ROA 14%, margin 30%). Balance sheet: $6.8B free cash flow. Analyst sentiment positive (4 raises, avg +21%). Insider selling cluster ($1.3M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $247.3B |
| Beta | 0.30 |
| 52W Range | $73.31 - $105.84 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.80 |
| Forward P/E | 11.5 |
| Current P/E | 11.0 |
| YoY Growth | -4.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.7% to -1.7% (+2.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.7pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.6%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.79), momentum weakening. RSI neutral at 57.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.71% (CS: 20) | Neutral |
| RSI_14 | 57.1 | Neutral |
| MACD Histogram | -0.79 | Bearish |
| vs SMA20 | 1.002x | Above |
| vs SMA50 | 1.082x | Above |
| vs SMA200 | 1.165x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $99.01
- **Stop Loss:** $93.83 (5.2% risk)
- **Target:** $104.19 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 266
- **Position Value:** $26,336.66
- **Portfolio %:** 26.34%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-03 (Est: $2.05)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.58 | +9.9% |
| 2025Q2 | $2.03 | $2.13 | +5.0% |
| 2025Q1 | $2.14 | $2.22 | +4.0% |
| 2024Q4 | $1.67 | $1.72 | +3.3% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*